Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 690 of 5804
-
New shot every 2 weeks could control tumor growth in gut cancers
Disease control OngoingThe purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label…
Phase: PHASE3 • Sponsor: Camurus AB • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New antibody targets hidden plasma cells to treat kidney disease
Disease control CompletedMembranous nephropathy (MN) - the leading cause of nephrotic syndrome (NS) in adults - is an immune-mediated disease that results from the deposition of immunoglobulins and complement components onto the sub-epithelial layer of the glomerular capillary wall. The availability for …
Phase: PHASE2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New DNA test could spare thousands from unnecessary thyroid surgery
Diagnosis Recruiting nowThis clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) fr…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
New hope for recurrent endometrial cancer: personalized combo therapy tested
Disease control Recruiting nowThis is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform fo…
Phase: PHASE1, PHASE2 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could zapping kidney nerves tame tough high blood pressure?
Disease control OngoingThe purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects prev…
Phase: NA • Sponsor: Medtronic Vascular • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Pedal power: could indoor cycling delay Alzheimer's in At-Risk seniors?
Prevention OngoingThe overall goal of the CYCLE-AD trial is to determine the role of long-term, high intensity exercise in slowing or delaying the onset of cognitive and AD-related brain changes in e4 carriers. Successful translation and demonstration of the effectiveness of a scalable home-based …
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Prevention
Last updated Jun 27, 2026 07:52 UTC
-
New drug targets Hard-to-Treat cancers in japanese patients
Disease control OngoingThe primary objectives of this study are as follows: Phase 1 (sequential dose-escalation): to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent and to determine the recommended Phase 2 dose (RP2D) of SG in Japanese participants with advanc…
Phase: PHASE1, PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Supercharged t cells aim to block COVID in vulnerable transplant patients
Prevention Recruiting nowThis is an open label, phase I dose-escalation study to evaluate the safety of coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell transplantation (HSCT). Participants will receive donor…
Phase: PHASE1 • Sponsor: Children's National Research Institute • Aim: Prevention
Last updated Jun 27, 2026 11:01 UTC
-
Could less hormone therapy be enough for High-Risk prostate cancer?
Disease control OngoingThe purpose of this study is to find out whether combining a shorter than standard course of ADT with standard prostate brachytherapy and hypofractionated external beam radiation therapy is a safe and effective way to prevent high-risk prostate cancer from coming back and/or spre…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for kids with severe gut disease: drug shows promise in remission
Disease control CompletedVedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe ulcerative colitis will be treated with vedolizumab. The main aim of the study is to check if participants achieve remissio…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Hair loss drug shows promise in Long-Term trial
Disease control CompletedThe overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, severe alopecia areata. Patients from European sites who previously completed a qualifying CTP-543 clin…
Phase: PHASE3 • Sponsor: Sun Pharmaceutical Industries, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug shows promise for Hard-to-Treat ovarian cancer
Disease control CompletedPICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expressi…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New combo therapy aims to outsmart aggressive lymphoma
Disease control OngoingThis study evaluates the addition of Acalabrutinib to current standard therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large B-cell Lymphoma (DLBCL) requiring full course chemo…
Phase: PHASE2 • Sponsor: University Hospital Southampton NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Eye drops could replace needles for diabetic eye swelling
Disease control CompletedThe primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS- 01 as compared to Vehicle in participants with Diabetic Macular Edema (DME).
Phase: PHASE2, PHASE3 • Sponsor: Oculis • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Mom's workout may shield baby from obesity
Prevention Recruiting nowThe overall objective of this proposal is to conduct a longitudinal prospective study of overweight/obese (OW/OB) pregnant women and their offspring to determine which prenatal exercise mode will have the greatest impact on maternal and infant cardiometabolic health. This informa…
Phase: NA • Sponsor: East Carolina University • Aim: Prevention
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis phase IB trial evaluates the effect of niraparib and TSR-042 in treating patients with BRCA-mutated breast, pancreas, ovary, fallopian tube, or primary peritoneal cancer that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). …
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Immunotherapy before surgery shows promise for certain cancers
Disease control OngoingThis trial is a multicenter, 3-cohort, prospective, Phase II trial conducted in patients with untreated resectable MSI/dMMR carcinomas and aiming to evaluate the safety and the efficacy of ICI (immune checkpoint inhibitor) as neoadjuvant treatment in these patients. We hypothesi…
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could a drug make milk allergy therapy safer and more effective?
Disease control TerminatedThis is a phase 2, multicenter, randomized, double-blind, parallel group, 2 arm study in approximately 40 subjects aged 4 to 50 years, inclusive, who are allergic to cow's milk. The primary objective is to assess whether dupilumab as an adjunct to milk oral immunotherapy (OIT) co…
Phase: PHASE2 • Sponsor: Andrew J Long, PharmD • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Booster breakthrough: mRNA shot supercharges immunity in inactivated vaccine recipients
⭐️ VACCINE ⭐️ Completed300 adults ≥30 years of age who have previously received two doses of an inactivated COVID-19 vaccine at least 3 months earlier will receive a third dose with an mRNA vaccine (BNT162b2, BioNTech). Investigators will monitor reactogenicity and measure the immune response to the th…
Phase: PHASE4 • Sponsor: The University of Hong Kong • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:33 UTC
-
New combo shows promise in shrinking melanoma before surgery
Disease control OngoingThis phase II trial studies the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with melanoma that can be treated by surgery (operable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC